Tilray Medical announced its participation in Cannabis Europa London 2026, a key event focused on medical cannabis policy and regulation in Europe. The event will gather policymakers, healthcare professionals, and industry leaders to discuss how clinical research and real-world evidence can shape effective cannabis policies. José Tempero, Tilray’s Director of International Medical Affairs, will join a panel titled “Evidence First: Designing Public Policy Through Data and Trials,” emphasizing the importance of data in developing responsible healthcare frameworks and improving patient access to medical cannabis.

This discussion is particularly relevant for individuals interested in how medical cannabis can enhance health outcomes. As access to cannabis-based treatments expands, understanding the evidence behind these products can help you make informed choices about your health. The focus on patient outcomes and scalable regulatory approaches aims to ensure that people can safely and effectively benefit from medical cannabis.

The event reflects ongoing efforts to establish a solid foundation for medical cannabis in Europe, with a strong emphasis on evidence-based practices. While this forum is not a clinical trial itself, it highlights the role of scientific research in shaping policies that could ultimately improve access to medical cannabis for patients across Europe. The discussions will contribute to a growing body of knowledge that informs future regulations and practices.

For those curious about medical cannabis, staying informed about such events and the evolving landscape can help you understand potential benefits and risks. Engaging with credible sources and healthcare professionals can guide you in making educated decisions regarding cannabis use for health and wellness.

Source: globenewswire.com